BBH:NSD-VanEck Vectors Biotech ETF (USD)

ETF | Health | NASDAQ Global Market

Last Closing

USD 158.56

Change

0.00 (0.00)%

Market Cap

USD 0.58B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors? US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Inception Date: 20/12/2011

Primary Benchmark: MVIS US Listed Biotech 25 NR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.4%

Management Expense Ratio: 0.35 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-22 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
IBB iShares Biotechnology ETF 0.47 %

+0.88 (+0.66%)

USD 6.91B
PPH VanEck Pharmaceutical ETF 0.36 %

+1.26 (+1.46%)

USD 0.61B
PSCH Invesco S&P SmallCap Health Ca.. 0.29 %

-0.09 (-0.20%)

USD 0.19B
PTH Invesco DWA Healthcare Momentu.. 0.60 %

-0.06 (-0.15%)

USD 0.14B
GNOM Global X Genomics & Biotechnol.. 0.00 %

+0.03 (+0.30%)

USD 0.07B
FTXH First Trust Nasdaq Pharmaceuti.. 0.60 %

+0.27 (+0.98%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET.. 0.79 %

+0.23 (+1.90%)

USD 0.01B

ETFs Containing BBH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.08% 38% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.08% 38% F 43% F
Trailing 12 Months  
Capital Gain -2.96% 38% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.96% 38% F 43% F
Trailing 5 Years  
Capital Gain 11.00% 63% D 59% D-
Dividend Return 1.73% 57% F 6% D-
Total Return 12.72% 63% D 53% F
Average Annual (5 Year Horizon)  
Capital Gain 1.69% 50% F 43% F
Dividend Return 2.06% 63% D 40% F
Total Return 0.37% 63% D 13% F
Risk Return Profile  
Volatility (Standard Deviation) 21.45% 63% D 75% C
Risk Adjusted Return 9.59% 63% D 41% F
Market Capitalization 0.58B 75% C 59% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike